/SPRO

SPRO Stock - Spero Therapeutics, Inc.

Q: What is the analyst price target for SPRO?

Analyst price target information is not currently available for SPRO.

Q: What is SPRO's market cap?

Market capitalization information is not currently available for SPRO.

Healthcare|Biotechnology|NASDAQ

$2.32+1.31%

+$0.03 (+1.31%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.55

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SPRO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.48

52W High$3.22

52W Low$0.51

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$47.98M	$103.78M	$48.58M	$3.07M	$9.33M
Gross Profit	$-48,780,000	$52.34M	$48.58M	$3.07M	$-57,673,000
Gross Margin	-101.7%	50.4%	100.0%	100.0%	-618.1%
Operating Income	$-73,361,000	$21.48M	$-42,197,000	$-87,971,000	$-79,113,000
Net Income	$-68,566,000	$22.81M	$-46,415,000	$-89,756,000	$-78,280,000
Net Margin	-142.9%	22.0%	-95.5%	-2923.6%	-839.0%
EPS	$-1.27	$0.43	$-1.23	$-2.91	$-3.52

Company Overview

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 180.2% Upside

Now

Low

Average

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 20th 2024	Evercore ISI	Downgrade	In-line	$5
September 23rd 2022	Evercore ISI	Upgrade	Outperform	$8← $2

Earnings History & Surprises

SPRO

Beat Rate

63%

Last 19 quarters

Avg Surprise

+121.5%

EPS vs Estimate

Beats / Misses

12/6

1 met exactly

Latest EPS

$-0.13

Q4 2025

EPS Surprise History

Q1 24

+1060.0%

$0.96vs$-0.10

Q2 24

-242.9%

$-0.24vs$-0.07

Q3 24

+5.7%

$-0.33vs$-0.35

Q4 24

-18.5%

$-0.32vs$-0.27

Q1 25

-8.6%

$-0.38vs$-0.35

Q2 25

+54.5%

$-0.25vs$-0.55

Q3 25

+92.1%

$-0.03vs$-0.38

Q4 25

+48.0%

$-0.13vs$-0.25

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 26, 2026	—	—	—	—
Q4 2025	Nov 13, 2025	$-0.25	$-0.13	+48.0%	✓ BEAT
Q3 2025	Aug 12, 2025	$-0.38	$-0.03	+92.1%	✓ BEAT
Q2 2025	May 13, 2025	$-0.55	$-0.25	+54.5%	✓ BEAT
Q1 2025	Mar 27, 2025	$-0.35	$-0.38	-8.6%	✗ MISS
Q4 2024	Nov 14, 2024	$-0.27	$-0.32	-18.5%	✗ MISS
Q3 2024	Aug 5, 2024	$-0.35	$-0.33	+5.7%	✓ BEAT
Q2 2024	May 15, 2024	$-0.07	$-0.24	-242.9%	✗ MISS
Q1 2024	Mar 13, 2024	$-0.10	$0.96	+1060.0%	✓ BEAT
Q4 2023	Nov 13, 2023	$-0.15	$0.02	+113.3%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.29	$-0.23	+20.7%	✓ BEAT
Q2 2023	May 11, 2023	$-0.35	$-0.25	+28.6%	✓ BEAT
Q1 2023	Mar 30, 2023	$0.04	$0.55	+1169.3%	✓ BEAT
Q4 2022	Nov 14, 2022	$-0.34	$-0.33	+2.9%	✓ BEAT
Q3 2022	Aug 10, 2022	$-0.88	$-0.87	+1.1%	✓ BEAT
Q2 2022	May 16, 2022	$-0.87	$-1.01	-16.1%	✗ MISS
Q1 2022	Mar 31, 2022	$-0.80	$-0.90	-12.5%	✗ MISS
Q4 2021	Nov 10, 2021	$-0.70	$-0.70	0.0%	= MET
Q3 2021	Aug 5, 2021	$-0.77	$-0.63	+18.2%	✓ BEAT
Q2 2021	May 6, 2021	$-0.61	$-0.66	-8.2%	✗ MISS

Frequently Asked Questions about SPRO

What is SPRO's current stock price?

Spero Therapeutics, Inc. (SPRO) is currently trading at $2.32 per share. The stock has moved +1.31% today.

What is the analyst price target for SPRO?

No analyst price targets are currently available for this stock.

What sector is Spero Therapeutics, Inc. in?

Spero Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is SPRO's market cap?

Spero Therapeutics, Inc. has a market capitalization of $0.13 billion, making it a small-cap company.

Does SPRO pay dividends?

No, Spero Therapeutics, Inc. does not currently pay a dividend to shareholders.